semaglutide evoke Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Semaglutide Misses Mark for Alzheimer

Future clinical trials should thus aim to identify the optimal combination of diet, physical activity protocols, and behavioral modification techniques to be combined with new pharmacotherapies, as this combination could have a multiplier beneficial effect on the management of obesity

10.1016/j.nut.2012.09.009 18

Contraindications BPC-157 peptide therapy is not recommended for individuals who: Have active or recent cancer Are pregnant or breastfeeding Are under the age of 18 A full medical consultation is required before starting any peptide protocol

Short Answer: BPC-157 is a synthetic peptide derived from a stomach-protein fragment that is promoted for healing and tissue repair